Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)

Jesús F San Miguel, MD PhD, Paul G. Richardson, MD, Robert Z. Orlowski, MD, PhD, Hartmut Goldschmidt, Deyanira Corzo, MD, Carol Satler, Dixie-Lee Esseltine, MD, FRCPC, Rachel Neuwirth, MS, Maria Ponsillo, MD, Andrew Z Cakana, MD, FRCPath, Jay King, MD, William M Deraedt, PhD, Avinash Desai, Yana Lutska, Dina Gifkins, PhD, Kevin Liu, PhD, Pieter Sonneveld, MD, PhD

Blood (2011) 118 (21): 2933.

https://doi.org/10.1182/blood.V118.21.2933.2933

Published: 2011

Journal Articles

Patient-Reported Quality of Life (QoL) in Elderly, Newly Diagnosed Multiple Myeloma (MM) Patients Receiving Bortezomib-Based Combinations: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Ruben Niesvizky, MD, Ian W. Flinn, MD, PhD, Robert Rifkin, MD, Nashat Gabrail, MD, Veena Charu, MD, Billy Clowney, MD, Yousuf Gaffar, MD, Thomas A. Warr, MD, FACP, Rachel Neuwirth, MS, Hui Huang, PhD, MBA, Sanggyu Choi, PhD, Deyanira Corzo, MD

Blood (2011) 118 (21): 1864.

https://doi.org/10.1182/blood.V118.21.1864.1864

Published: 2011

Journal Articles

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Ruben Niesvizky, MD, Ian W. Flinn, MD, PhD, Robert Rifkin, MD, Nashat Gabrail, MD, Veena Charu, MD, Billy Clowney, MD, James Essell, MD, Yousuf Gaffar, MD, Thomas A. Warr, MD, FACP, Rachel Neuwirth, MS, Deyanira Corzo, MD, James Reeves, MD

Blood (2011) 118 (21): 478.

https://doi.org/10.1182/blood.V118.21.478.478

Published: 2011

Journal Articles

Patient-Reported Quality of Life In Elderly, Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Results From the Phase 3b UPFRONT Study

Ruben Niesvizky, MD, Ian W. Flinn, MD, PhD, Robert M. Rifkin, MD, Nashat Y Gabrail, MD, Veena Charu, MD, Billy Clowney, MD, James Essell, MD, Yousuf A Gaffar, MD, Thomas A. Warr, MD, Rachel Neuwirth, MS, Deyanira Corzo, MD, James A Reeves, MD

Blood (2010) 116 (21): 3026.

https://doi.org/10.1182/blood.V116.21.3026.3026

Published: 2010

Journal Articles

Herpes Zoster (HZ) Complicating Bortezomib Therapy of Relapsed/Refractory Indolent B-Cell and Mantle Cell Lymphoma: An Analysis of Two Phase II Trials.

Vicki A. Morrison, MD, Richard I Fisher, MD, Andre Goy, MD, Sven de Vos, Steven H. Bernstein, Anthony Boral, MD, PhD, Rachel Neuwirth, MS

Blood (2010) 116 (21): 2818.

https://doi.org/10.1182/blood.V116.21.2818.2818

Published: 2010

Journal Articles

Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study.

Michael Craig, MD, Wahid T Hanna, MD, Fernando Cabanillas, MD, Chien-Shing Chen, MD, PhD, Sudha Parasuraman, MD, Rachel Neuwirth, MS, Owen A. O'Connor, MD, PhD

Blood (2010) 116 (21): 2798.

https://doi.org/10.1182/blood.V116.21.2798.2798

Published: 2010

Journal Articles

Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle

Pooja S. Raibagkar, MD, Paul G Richardson, Pieter Sonneveld, Michael W. Schuster, MD, David Irwin, MD, Edward A. Stadtmauer, MD, Thierry Facon, MD, Jean-Luc Harousseau, MD, Dina Ben-Yehuda, Sagar Lonial, MD, Hartmut Goldschmidt, Donna E. Reece, MD, Jesus F San Miguel, Joan Blade, Mario Boccadoro, Rachel Neuwirth, MS, Dixie-Lee Esseltine, MD, FRCPC, Kenneth C. Anderson, Nikhil C. Munshi, MD

Blood (2010) 116 (21): 1963.

https://doi.org/10.1182/blood.V116.21.1963.1963

Published: 2010

Journal Articles

Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients

Blood (2010) 116 (21): 619.

https://doi.org/10.1182/blood.V116.21.619.619

Published: 2010

NARROW

Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)

Patient-Reported Quality of Life (QoL) in Elderly, Newly Diagnosed Multiple Myeloma (MM) Patients Receiving Bortezomib-Based Combinations: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Patient-Reported Quality of Life In Elderly, Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Results From the Phase 3b UPFRONT Study

Herpes Zoster (HZ) Complicating Bortezomib Therapy of Relapsed/Refractory Indolent B-Cell and Mantle Cell Lymphoma: An Analysis of Two Phase II Trials.

Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study.

Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle

Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only